Normal Tissue Complications following Hypofractionated Chest Wall Radiotherapy in Breast Cancer Patients and Their Correlation with Patient, Tumor, and Treatment Characteristics

Mohsin Khan; Shahid A Siddiqui; Manoj K Gupta; Rajeev K Seam; Manish Gupta

doi:10.4103/ijmpo.ijmpo_80_16

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(02): 121-127
DOI: 10.4103/ijmpo.ijmpo_80_16

Original Article

Normal Tissue Complications following Hypofractionated Chest Wall Radiotherapy in Breast Cancer Patients and Their Correlation with Patient, Tumor, and Treatment Characteristics

Mohsin Khan

Department of Radiotherapy, JNMC, AMU, Aligarh, Uttar Pradesh, India

,

Shahid A Siddiqui

Department of Radiotherapy, JNMC, AMU, Aligarh, Uttar Pradesh, India

,

Manoj K Gupta

Department of Radiotherapy, IGMC, Shimla, Himachal Pradesh, India

,

Rajeev K Seam

Department of Radiotherapy, IGMC, Shimla, Himachal Pradesh, India

,

Manish Gupta

Department of Radiotherapy, IGMC, Shimla, Himachal Pradesh, India

› Author Affiliations

Abstract

PDF Download

Abstract

Introduction: Normal tissue complications following chest wall radiotherapy (RT) are inevitable, and the long-term data on hypofractionation are still limited. To quantify the late effects of hypofractionated RT on cardiac, pulmonary, brachial plexus, and regional lymphatics and their correlation with patient, tumor, and treatment characteristics is the main objective of this study. Materials and Methods: Two hundred and sixteen breast cancer patients following mastectomy were treated with hypofractionated schedules either 40 Gy in 15 fractions or 42.5 Gy in 16 fractions. Common Toxicity Criteria version 3.0 was utilized to quantify the late effects of hypofractionation on cardiac, pulmonary, brachial plexus, and lymphedema at a maximum follow-up of 5 years. Results: Median follow-up was 42 months. Median age was 49 years. 14.8% developed ≥Grade (Gr) 2 late cardiac toxicity. 10.2% developed ≥Gr2 late pulmonary toxicity. There were 28.7% patients who developed ≥Gr2 lymphedema. Sixty-seven out of 216 patients had symptomatic brachial plexopathy at 5-year follow-up. Variables found to increase the incidence of these adverse events included smoking, hypertension, diabetes mellitus, body mass index ≥25, extent of axillary dissection, and use of supraclavicular field. Conclusion: Hypofractionation leads to increased risk of normal tissue complications partly influenced by some patient- and treatment-related factors, but these were manageable and minimally disabling.

Keywords

Breast cancer - hypofractionation - postmastectomy

PDF (509 kb)

References

References
1 Fletcher GH. Clinical dose response curve of subclinical aggregates of epithelial cells and its practical application in the management of human cancer. In: Friedman M, editor. Biological and Clinical Basis of Radiosensitivity. Springfield, IL: Charles C. Thomas; 1974. p. 485.
2 START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol 2008;9:331-41.
3 START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet 2008;371:1098-107.
4 Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: Long-term results of a randomised trial. Lancet Oncol 2006;7:467-71.
5 Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:1143-50.
6 Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 1990;19:219-35.
7 Cox JD. Large-dose fractionation (hypofractionation). Cancer 1985;55 9 Suppl: 2105-11.
8 Langberg CW, Hauer-Jensen M. Influence of fraction size on the development of late radiation enteropathy. An experimental study in the rat. Acta Oncol 1996;35:89-94.
9 Wang EH, Sekyi-Otu A, O'Sullivan B, Bell RS. Management of long-term postirradiation periclavicular complications. J Surg Oncol 1992;51:259-65.
10 Bates T, Evans RG. Report of the Independent Review Commissioned by the Royal College of Radiologists into Brachial Plexus Neuropathy Following Radiotherapy for Breast Carcinoma. London: Royal College of Radiologists; 1995.
11 Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: Nationwide cohort study of 90 000 Swedish women. BMJ 2003;326:256-7.
12 Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99:365-75.
13 King V, Constine LS, Clark D, Schwartz RG, Muhs AG, Henzler M, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1996;36:881-9.
14 Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998;16:3493-501.
15 Lind PA, Rosfors S, Wennberg B, Glas U, Bevegård S, Fornander T. Pulmonary function following adjuvant chemotherapy and radiotherapy for breast cancer and the issue of three-dimensional treatment planning. Radiother Oncol 1998;49:245-54.
16 Ooi GC, Kwong DL, Ho JC, Lock DT, Chan FL, Lam WK, et al. Pulmonary sequelae of treatment for breast cancer: A prospective study. Int J Radiat Oncol Biol Phys 2001;50:411-9.
17 Lind PA, Marks LB, Hardenbergh PH, Clough R, Fan M, Hollis D, et al. Technical factors associated with radiation pneumonitis after local +/regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys 2002;52:137-43.
18 Johansson S, Bjermer L, Franzen L, Henriksson R. Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients. Radiother Oncol 1998;49:41-7.
19 Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, et al. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 2004;96:1676-81.
20 Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996;88:918-22.
21 Wennberg B, Gagliardi G, Sundbom L, Svane G, Lind P. Early response of lung in breast cancer irradiation: Radiologic density changes measured by CT and symptomatic radiation pneumonitis. Int J Radiat Oncol Biol Phys 2002;52:1196-206.
22 Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1991;21:355-60.
23 Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): A phase 2 randomised trial. Lancet Oncol 2010;11:258-65.
24 Recht A. Radiotherapy, antihormonal therapy, and personalised medicine. Lancet Oncol 2010;11:215-6.
25 Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, et al. Lymphedema in breast cancer survivors: Incidence, degree, time course, treatment, and symptoms. J Clin Oncol 2009;27:390-7.
26 Segerström K, Bjerle P, Graffman S, Nyström A. Factors that influence the incidence of brachial oedema after treatment of breast cancer. Scand J Plast Reconstr Surg Hand Surg 1992;26:223-7.
27 Böhler FK, Rhomberg W, Doringer W. Hypertension as risk factor for increased rate of side effects in the framework of breast carcinoma irradiation. Strahlenther Onkol 1992;168:344-9.
28 Fowble BL, Solin LJ, Schultz DJ, Goodman RL. Ten year results of conservative surgery and irradiation for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 1991;21:269-77.
29 Pierce SM, Recht A, Lingos TI, Abner A, Vicini F, Silver B, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992;23:915-23.
30 Galecki J, Hicer-Grzenkowicz J, Grudzien-Kowalska M, Michalska T, Zalucki W. Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer – A review. Acta Oncol 2006;45:280-4.